Time to read
4 minutes
Read so far

Obesity accelerates tumour growth by impairing immune cell function

Wed, 12/09/2020 - 12:00
Posted in:

Harvard Medical School (HMS) researchers have discovered that obesity allows cancer cells to outcompete tumour-killing immune cells in a battle for fuel, findings that could have significant implications for cancer immunotherapy.

Obesity has been linked to increased risk for over a dozen different types of cancer, as well as worse prognosis and survival. Over the years, scientists have identified obesity-related processes that drive tumour growth, such as metabolic changes and chronic inflammation, up until now a detailed understanding of the interplay between obesity and cancer has remained elusive.

In the mice study, ‘Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity, published in Cell,  the research team report that a high-fat diet reduces the numbers and antitumour activity of CD8+ T cells, a critical type of immune cell, inside tumours. This occurs because cancer cells reprogram their metabolism in response to increased fat availability to better gobble up energy-rich fat molecules, depriving T cells of fuel and accelerating tumour growth.

"Putting the same tumour in obese and non-obese settings reveals that cancer cells rewire their metabolism in response to a high fat diet," said Dr Marcia Haigis, professor of cell biology in the Blavatnik Institute at HMS and co-senior author of the study. "This finding suggests that a therapy that would potentially work in one setting might not be as effective in another, which needs to be better understood given the obesity epidemic in our society."

The team found that blocking this fat-related metabolic reprogramming significantly reduced tumour volume in mice on high-fat diets. Because CD8+ T cells are the main weapon used by immunotherapies that activate the immune system against cancer, the study results suggest new strategies for improving such therapies.

"Cancer immunotherapies are making an enormous impact on patients' lives, but they do not benefit everyone," said co-senior author, Dr Arlene Sharpe, the HMS George Fabyan Professor of Comparative Pathology and chair of the Department of Immunology in the Blavatnik Institute. "We now know there is a metabolic tug-of-war between T cells and tumour cells that changes with obesity. Our study provides a roadmap to explore this interplay, which can help us to start thinking about cancer immunotherapies and combination therapies in new ways."

Haigis, Sharpe and colleagues investigated the effects of obesity on mouse models of different types of cancer, including colorectal, breast, melanoma and lung. Led by study co-first authors, Drs Alison Ringel and Jefte Drijvers, the team gave mice normal or high-fat diets, the latter leading to increased body weight and other obesity-related changes. They then looked at different cell types and molecules inside and around tumours, together called the tumour microenvironment.

The researchers found that tumours grew much more rapidly in animals on high-fat diets compared to those on normal diets. But this occurred only in cancer types that are immunogenic, which can contain high numbers of immune cells; are more easily recognized by the immune system; and are more likely to provoke an immune response.

Experiments revealed that diet-related differences in tumour growth depended specifically on the activity of CD8+ T cells, immune cells that can target and kill cancer cells. Diet did not affect tumour growth rate if CD8+ T cells were eliminated experimentally in mice.

Strikingly, high-fat diets reduced the presence of CD8+ T cells in the tumour microenvironment, but not elsewhere in the body. Those remaining in the tumour were less robust - they divided more slowly and had markers of decreased activity. But when these cells were isolated and grown in a lab, they had normal activity, suggesting something in the tumour impaired these cells' function.

The team also encountered an apparent paradox. In obese animals, the tumour microenvironment was depleted of key free fatty acids, a major cellular fuel source, even though the rest of the body was enriched in fats, as expected in obesity.

These clues pushed the researchers to craft a comprehensive atlas of the metabolic profiles of different cell types in tumours under normal and high-fat diet conditions.

The analyses revealed that cancer cells adapted in response to changes in fat availability. Under a high-fat diet, cancer cells were able to reprogramme their metabolism to increase fat uptake and utilization, while CD8+ T cells did not. This ultimately depleted the tumour microenvironment of certain fatty acids, leaving T cells starved for this essential fuel.

"The paradoxical depletion of fatty acids was one of the most surprising findings of this study. It really blew us away and it was the launch pad for our analyses," said Ringel, a postdoctoral fellow in the Haigis lab. "That obesity and whole-body metabolism can change how different cells in tumours utilize fuel was an exciting discovery, and our metabolic atlas now allows us to dissect and better understand these processes."

Through several different approaches, including single-cell gene expression analyses, large-scale protein surveys and high-resolution imaging, the team identified numerous diet-related changes to metabolic pathways of both cancer and immune cells in the tumour microenvironment.

Of particular interest was PHD3, a protein that in normal cells has been shown to act as a brake on excessive fat metabolism. Cancer cells in an obese environment had significantly lower expression of PHD3 compared to in a normal environment. When the researchers forced tumour cells to overexpress PHD, they found that this diminished a tumour's ability to take up fat in obese mice. It also restored the availability of key free fatty acids in the tumour microenvironment.

Increased PHD3 expression largely reversed the negative effects of a high-fat diet on immune cell function in tumours. Tumours with high PHD3 grew slower in obese mice, compared to tumours with low PHD3. This was a direct result of increased CD8+ T cell activity. In obese mice lacking CD8+ T cells, tumour growth was unaffected by differences in PHD3 expression.

The team also analysed human tumour databases and found that low PHD3 expression was associated with immunologically ‘cold’ tumours, defined by fewer numbers of immune cells. This association suggested that tumour fat metabolism plays a role in human disease, and that obesity reduces antitumour immunity in multiple cancer types, the authors said.

"CD8+ T cells are the central focus of many promising precision cancer therapies, including vaccines and cell therapies such as CAR-T," added Sharpe. "These approaches need T cells to have sufficient energy to kill cancer cells, but at the same time we don't want tumours to have fuel to grow. We now have amazingly comprehensive data for studying this dynamic and determining mechanisms that prevent T cells from functioning as they should."

More broadly, the results serve as a foundation for efforts to better understand how obesity affects cancer and the impact of patient metabolism on therapeutic outcomes, the authors said. While it's too early to tell if PHD3 is the best therapeutic target, the findings open the door for new strategies to combat cancer through its metabolic vulnerabilities, they said.

"We're interested in identifying pathways that we could use as potential targets to prevent cancer growth and to increase immune antitumour function," concluded Haigis. "Our study provides a high-resolution metabolic atlas to mine for insights into obesity, tumour immunity and the crosstalk and competition between immune and tumour cells. There are likely many other cell types involved and many more pathways to be explored."